Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $100,200.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 30,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $3.34, for a total transaction of $100,200.00. Following the completion of the transaction, the director owned 6,158,287 shares of the company’s stock, valued at $20,568,678.58. This represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, August 4th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.25, for a total transaction of $97,500.00.
• On Tuesday, July 7th, Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.96, for a total transaction of $158,400.00.

Recursion Pharmaceuticals Trading Up 5.5%

NASDAQ RXRX opened at $3.63 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $2.77 and a 52 week high of $7.18. The company has a 50 day moving average price of $3.33 and a 200 day moving average price of $3.34. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.94 billion, a PE ratio of -3.49 and a beta of 1.07.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.The firm had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $10.97 million. During the same period in the prior year, the firm posted ($0.41) earnings per share. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.92 EPS for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of RXRX. International Assets Investment Management LLC purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth $31,000. Integral Investment Advisors Inc. purchased a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth about $39,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $41,000. MQS Management LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $41,000. Finally, Fund Advisors of America Inc FL purchased a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at about $45,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on RXRX shares. Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Finally, Morgan Stanley set a $5.30 price objective on shares of Recursion Pharmaceuticals in a report on Monday, August 17th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $8.06.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.